Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways
Baiying Qingmai Formulation (BF) is a classical clinical prescription used for decades to treat thromboangiitis obliterans (TAO). Although it effectively relieves pain and ischemic ulcers in patients with TAO, its anti-TAO mechanisms remain unclear. The chemical components of BF were analyzed using...
Main Authors: | Chongchong Zou, Li Liu, Chuanqi Huang, Song Hu |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1018438/full |
Similar Items
-
Smoking characteristics and cessation in patients with thromboangiitis obliterans
by: C.A. Jiménez-Ruiz, et al.
Published: (2016-02-01) -
Thromboangiitis obliterans (Buerger disease)
by: Jessica Seebald, BS, et al.
Published: (2015-10-01) -
Thromboangiitis obliterans (Buerger's disease) - a review
by: Rafał Bogacz, et al.
Published: (2023-08-01) -
True leukonychia as the presenting sign of early thromboangiitis obliterans
by: Mohammed S. Hamid, BS, et al.
Published: (2024-03-01) -
Buerger’s disease or thromboangiitis obliterans: description of two cases
by: Carlo Umberto Manzini, et al.
Published: (2019-12-01)